| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| sorafenib | serine/threonine-protein kinase b-raf | small molecule | NA | drugbank , DGIDB | Renal Cell Carcinoma[MeSHID:D002292] Liver carcinoma[MeSHID:D006528] MYELODYSPLASTIC SYNDROME[MeSHID:D009190] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.3 | approved,investigational | inhibitor |
| sorafenib | epidermal growth factor receptor | NA | Successful target | TTD , DGIDB | Renal Cell Carcinoma[MeSHID:D002292] Liver carcinoma[MeSHID:D006528] MYELODYSPLASTIC SYNDROME[MeSHID:D009190] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.03 | approved | unknown |
| sorafenib | fibroblast growth factor receptor 1 | small molecule | NA | drugbank , DGIDB | Renal Cell Carcinoma[MeSHID:D002292] Liver carcinoma[MeSHID:D006528] MYELODYSPLASTIC SYNDROME[MeSHID:D009190] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.07 | approved,investigational | inhibitor |
| sorafenib | vascular endothelial growth factor receptor 1 | small molecule | NA | drugbank , DGIDB | Renal Cell Carcinoma[MeSHID:D002292] Liver carcinoma[MeSHID:D006528] MYELODYSPLASTIC SYNDROME[MeSHID:D009190] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.07 | approved,investigational | inhibitor |
| sorafenib | receptor-type tyrosine-protein kinase flt3 | small molecule | NA | drugbank , DGIDB | Renal Cell Carcinoma[MeSHID:D002292] Liver carcinoma[MeSHID:D006528] MYELODYSPLASTIC SYNDROME[MeSHID:D009190] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.33 | approved,investigational | antagonist |
| sorafenib | receptor-type tyrosine-protein kinase flt3 | small molecule | NA | drugbank , DGIDB | Renal Cell Carcinoma[MeSHID:D002292] Liver carcinoma[MeSHID:D006528] MYELODYSPLASTIC SYNDROME[MeSHID:D009190] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.33 | approved,investigational | antagonist,inhibitor |
| sorafenib | vascular endothelial growth factor receptor 3 | small molecule | NA | drugbank , DGIDB | Renal Cell Carcinoma[MeSHID:D002292] Liver carcinoma[MeSHID:D006528] MYELODYSPLASTIC SYNDROME[MeSHID:D009190] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.11 | approved,investigational | antagonist,inhibitor |
| sorafenib | vascular endothelial growth factor receptor 3 | small molecule | NA | drugbank , DGIDB | Renal Cell Carcinoma[MeSHID:D002292] Liver carcinoma[MeSHID:D006528] MYELODYSPLASTIC SYNDROME[MeSHID:D009190] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.11 | approved,investigational | antagonist |
| sorafenib | vascular endothelial growth factor receptor 2 | small molecule | Successful target | TTD , drugbank , DGIDB | Renal Cell Carcinoma[MeSHID:D002292] Liver carcinoma[MeSHID:D006528] MYELODYSPLASTIC SYNDROME[MeSHID:D009190] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.15 | approved,investigational | antagonist,inhibitor |
| sorafenib | vascular endothelial growth factor receptor 2 | small molecule | Successful target | TTD , drugbank , DGIDB | Renal Cell Carcinoma[MeSHID:D002292] Liver carcinoma[MeSHID:D006528] MYELODYSPLASTIC SYNDROME[MeSHID:D009190] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.15 | approved,investigational | antagonist |
| sorafenib | mast/stem cell growth factor receptor kit | small molecule | NA | drugbank , DGIDB | Renal Cell Carcinoma[MeSHID:D002292] Liver carcinoma[MeSHID:D006528] MYELODYSPLASTIC SYNDROME[MeSHID:D009190] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.3 | approved,investigational | antagonist |
| sorafenib | mast/stem cell growth factor receptor kit | small molecule | NA | drugbank , DGIDB | Renal Cell Carcinoma[MeSHID:D002292] Liver carcinoma[MeSHID:D006528] MYELODYSPLASTIC SYNDROME[MeSHID:D009190] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.3 | approved,investigational | antagonist,inhibitor |
| sorafenib | tyrosine-protein kinase kit | NA | Successful target | TTD , DGIDB | Renal Cell Carcinoma[MeSHID:D002292] Liver carcinoma[MeSHID:D006528] MYELODYSPLASTIC SYNDROME[MeSHID:D009190] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.3 | approved | inhibitor |
| sorafenib | tyrosine-protein kinase kit | NA | Successful target | TTD , DGIDB | Renal Cell Carcinoma[MeSHID:D002292] Liver carcinoma[MeSHID:D006528] MYELODYSPLASTIC SYNDROME[MeSHID:D009190] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.3 | approved | unknown |
| sorafenib | platelet-derived growth factor receptor beta | small molecule | Successful target | TTD , drugbank , DGIDB | Renal Cell Carcinoma[MeSHID:D002292] Liver carcinoma[MeSHID:D006528] MYELODYSPLASTIC SYNDROME[MeSHID:D009190] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.14 | approved,investigational | antagonist |
| sorafenib | platelet-derived growth factor receptor beta | small molecule | Successful target | TTD , drugbank , DGIDB | Renal Cell Carcinoma[MeSHID:D002292] Liver carcinoma[MeSHID:D006528] MYELODYSPLASTIC SYNDROME[MeSHID:D009190] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.14 | approved,investigational | antagonist,inhibitor |
| sorafenib | raf proto-oncogene serine/threonine-protein kinase | small molecule | NA | drugbank , DGIDB | Renal Cell Carcinoma[MeSHID:D002292] Liver carcinoma[MeSHID:D006528] MYELODYSPLASTIC SYNDROME[MeSHID:D009190] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.47 | approved,investigational | inhibitor |
| sorafenib | proto-oncogene tyrosine-protein kinase receptor ret | small molecule | NA | drugbank , DGIDB | Renal Cell Carcinoma[MeSHID:D002292] Liver carcinoma[MeSHID:D006528] MYELODYSPLASTIC SYNDROME[MeSHID:D009190] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.15 | approved,investigational | inhibitor |
| click here to return to the previous page | ||||||||